In This Article:
As global markets continue to show resilience and growth stocks outpace value shares, Sweden's market is also benefiting from this positive sentiment. In this context, companies with high insider ownership often stand out as they signal strong confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership In Sweden
| Name | Insider Ownership | Earnings Growth |
| CTT Systems (OM:CTT) | 16.9% | 24.8% |
| Truecaller (OM:TRUE B) | 29.5% | 21.6% |
| Fortnox (OM:FNOX) | 21.1% | 22.6% |
| Biovica International (OM:BIOVIC B) | 18.8% | 73.8% |
| Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
| Yubico (OM:YUBICO) | 37.5% | 43.7% |
| BioArctic (OM:BIOA B) | 34% | 102.8% |
| KebNi (OM:KEBNI B) | 37.8% | 86.1% |
| Calliditas Therapeutics (OM:CALTX) | 12.7% | 51.9% |
| InCoax Networks (OM:INCOAX) | 18.1% | 115.5% |
Underneath we present a selection of stocks filtered out by our screen.
BioArctic
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) is a Swedish company that develops biological drugs for central nervous system disorders and has a market cap of SEK14.05 billion.
Operations: BioArctic's revenue segment includes SEK252.21 million from its biotechnology division.
Insider Ownership: 34%
BioArctic's revenue is forecast to grow at 39.6% annually, outpacing the Swedish market and surpassing 20% per year. The company is expected to achieve profitability within three years, with earnings projected to grow by 102.8% annually. Despite recent high share price volatility, BioArctic trades at a significant discount to its estimated fair value and has seen insider buying in the last three months. Recent approvals of Leqembi for Alzheimer's treatment in multiple countries further bolster its growth prospects.
-
Navigate through the intricacies of BioArctic with our comprehensive analyst estimates report here.
-
Our expertly prepared valuation report BioArctic implies its share price may be lower than expected.
EQT
Simply Wall St Growth Rating: ★★★★★☆
Overview: EQT AB (publ) is a global private equity firm specializing in private capital and real asset segments, with a market cap of SEK405.21 billion.
Operations: The company's revenue segments include Central (€37.20 million), Real Assets (€878.70 million), and Private Capital (€1.28 billion).
Insider Ownership: 30.9%
EQT AB has shown substantial growth, with earnings increasing by 384.2% over the past year and revenue expected to grow at 17.9% annually, outpacing the Swedish market. Despite significant insider selling recently, the company's high insider ownership aligns interests with shareholders. EQT is actively pursuing strategic acquisitions, including potential bids for Compass Education and JB Chemicals & Pharmaceuticals. The firm also initiated a share repurchase program to optimize capital structure and support future growth initiatives.